{"protocolSection":{"identificationModule":{"nctId":"NCT01895855","orgStudyIdInfo":{"id":"PXVX-VC-200-003"},"organization":{"fullName":"Bavarian Nordic","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose Live Oral Cholera Vaccine, PXVX0200 CVD 103-HgR, in Preventing Cholera Following Challenge With Vibrio Cholerae 10 Days or 3 Months After Vaccination"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-09"},"primaryCompletionDateStruct":{"date":"2014-11","type":"ACTUAL"},"completionDateStruct":{"date":"2014-11","type":"ACTUAL"},"studyFirstSubmitDate":"2013-07-05","studyFirstSubmitQcDate":"2013-07-10","studyFirstPostDateStruct":{"date":"2013-07-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-07-05","resultsFirstSubmitQcDate":"2021-03-05","resultsFirstPostDateStruct":{"date":"2021-04-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-26","lastUpdatePostDateStruct":{"date":"2023-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bavarian Nordic","class":"INDUSTRY"},"collaborators":[{"name":"Emergent BioSolutions","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of the study is to determine if PXVX0200 is safe and effective in preventing cholera infection","detailedDescription":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose of Live Oral Cholera Vaccine Candidate, PXVX0200 CVD 103-HgR Strain, in Preventing Cholera following Challenge with Vibrio cholerae O1 El Tor Inaba 10 Days or 3 Months after Vaccination in volunteers aged 18-45 years"},"conditionsModule":{"conditions":["Cholera"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":197,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"PXVX0200","type":"EXPERIMENTAL","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU","interventionNames":["Biological: PXVX0200"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Biological: Placebo physiological saline","interventionNames":["Biological: placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"PXVX0200","description":"Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8","armGroupLabels":["PXVX0200"]},{"type":"BIOLOGICAL","name":"placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"% of Participants With Moderate to Severe Diarrhea","description":"Determine whether a single dose of PXVX0200 provides significantly greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination. The primary endpoint was the occurrence of moderate or severe (\\>/= 3 liters) diarrhea.","timeFrame":"Ten days after vaccination"},{"measure":"% of Participants With Moderate to Severe Diarrhea","description":"Determine whether a single dose of PXVX0200 provides significant greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination. The primary endpoint was the occurrence of moderate or severe (\\>/= 3 liters) of diarrhea.","timeFrame":"Ninety days after vaccination"}],"secondaryOutcomes":[{"measure":"Total Weight of Diarrheal Stools Following the 10 Day Cholera Challenge","description":"Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 10 day cholera challenge.","timeFrame":"Through 10 Days following challenge"},{"measure":"Total Weight of Diarrheal Stools Following the 90 Day Cholera Challenge","description":"Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 90 day cholera challenge.","timeFrame":"Through 10 Days following challenge"},{"measure":"% of Participants With Diarrhea of Any Severity Following a 10 Day Cholera Challenge","description":"Incidence of mild or worse (any severity) diarrhea following the 10 day cholera challenge.","timeFrame":"Through 10 Days following challenge"},{"measure":"% of Participants With Diarrhea of Any Severity Following a 90 Day Challenge","description":"Incidence of mild or worse (any severity) diarrhea following the 90 day cholera challenge.","timeFrame":"Through 10 Days following challenge"},{"measure":"% of Participants With Fever Following the 10 Day Cholera Challenge","description":"Incidence of mild or worse fever following the 10 day cholera challenge.","timeFrame":"Through 10 Days following challenge"},{"measure":"% of Participants With Fever Following the 90 Day Cholera Challenge","description":"Incidence of mild or worse fever following the 90 day cholera challenge.","timeFrame":"Through 10 Days following challenge"},{"measure":"Number of Days With Fecal Shedding Following 10 Day Challenge","description":"Number of days of fecal shedding of wild type V. cholerae following 10 Day Challenge.","timeFrame":"Through 10 Days post challenge"},{"measure":"Number of Days With Fecal Shedding Following 90 Day Challenge","description":"Number of days of fecal shedding of wild type V. cholerae following 90 Day Challenge","timeFrame":"Through 10 days following challenge"},{"measure":"# of Days With Positive Stool Culture Following 10 Day Cholera Challenge","description":"Total number of days with a positive stool culture following the 10 Day Cholera challenge.","timeFrame":"Through 10 Days following challenge"},{"measure":"# of Days With Positive Stool Culture Following 90 Day Cholera Challenge","description":"Total number of days with a positive stool culture following 90 Day Cholera Challenge","timeFrame":"Through 10 Days following challenge"},{"measure":"% of Participants With Reactogenicity, Diarrhea, Fever or Unsolicited Adverse Events Following Vaccination","description":"Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever following vaccination (through Day 8).\n\nIncidence and severity of unsolicited adverse events following vaccination (through Day 29).","timeFrame":"Following vaccination (Days 1 - 8) and to Day 29"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* healthy men or women,\n* age 18 to 45 years inclusive;\n* normal medical history and physical examination; and\n* no clinically significant abnormalities from:\n* urine dipstick for glucose, protein, and blood\n* complete blood count,\n* serum hepatic transaminases,\n* total bilirubin (direct if abnormal),\n* creatinine,\n* electrolytes,\n* albumin, or\n* electrocardiogram.\n* Women must have a negative pregnancy test.\n\nExclusion Criteria:\n\n* travel to a cholera endemic area in the previous 5 years;\n* abnormal stool pattern or regular use of laxatives;\n* history of eating disorders (such as bulimia), anal or rectal disorders, allergy to tetracycline and/or ciprofloxacin;\n* history of cholera or enterotoxigenic E. coli challenge or infection;\n* current or recent antibiotic use;\n* pregnancy or nursing;\n* positive serology for HIV, hepatitis B antigen, or hepatitis C;\n* any immunosuppressive medical condition;\n* history of hospitalization for psychiatric illness or use of specific psychiatric drugs.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"James McCarty, MD","affiliation":"Emergent BioSolutions","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Maryland Baltimore","city":"Baltimore","state":"Maryland","zip":"21201","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Cincinnati Children'S Hospital Medical Center","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"University of Vermont","city":"Burlington","state":"Vermont","zip":"05405","country":"United States","geoPoint":{"lat":44.47588,"lon":-73.21207}}]},"referencesModule":{"references":[{"pmid":"27001804","type":"RESULT","citation":"Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016 Jun 1;62(11):1329-1335. doi: 10.1093/cid/ciw145. Epub 2016 Mar 21."},{"pmid":"29655627","type":"RESULT","citation":"Haney DJ, Lock MD, Gurwith M, Simon JK, Ishioka G, Cohen MB, Kirkpatrick BD, Lyon CE, Chen WH, Sztein MB, Levine MM, Harris JB. Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection. Vaccine. 2018 May 11;36(20):2768-2773. doi: 10.1016/j.vaccine.2018.04.011. Epub 2018 Apr 11."},{"pmid":"28566334","type":"RESULT","citation":"Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. Antibody-Based Correlates of Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naive Population. Clin Vaccine Immunol. 2017 May 31;24(8):e00098-17. doi: 10.1128/CVI.00098-17. Online ahead of print."},{"pmid":"31743334","type":"DERIVED","citation":"Hossain M, Islam K, Kelly M, Mayo Smith LM, Charles RC, Weil AA, Bhuiyan TR, Kovac P, Xu P, Calderwood SB, Simon JK, Chen WH, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Leung DT, Azman AS, Harris JB, Qadri F, Ryan ET. Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba. PLoS Negl Trop Dis. 2019 Nov 19;13(11):e0007874. doi: 10.1371/journal.pntd.0007874. eCollection 2019 Nov."},{"pmid":"29624592","type":"DERIVED","citation":"Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, Kovac P, Xu P, LaRocque RC, Calderwood SB, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB, Qadri F, Ryan ET. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376. doi: 10.1371/journal.pntd.0006376. eCollection 2018 Apr."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10\\^8 to 2x10\\^9 CFU in a liquid suspension"},{"id":"FG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"95"},{"groupId":"FG001","numSubjects":"102"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"95"},{"groupId":"FG001","numSubjects":"102"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10\\^8 to 2x10\\^9 CFU in a liquid suspension"},{"id":"BG001","title":"Placebo","description":"Biological: Placebo physiological saline"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"197"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"197"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31.5","lowerLimit":"18","upperLimit":"45"},{"groupId":"BG001","value":"30.6","lowerLimit":"18","upperLimit":"45"},{"groupId":"BG002","value":"31.0","lowerLimit":"18","upperLimit":"45"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"73"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"124"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"186"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"133"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"58"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"197"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"% of Participants With Moderate to Severe Diarrhea","description":"Determine whether a single dose of PXVX0200 provides significantly greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination. The primary endpoint was the occurrence of moderate or severe (\\>/= 3 liters) diarrhea.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Ten days after vaccination","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200\n\nSingle dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"59.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The lower, two sided 95% confidence bound on protective efficacy must be \\>/= 30%.","paramType":"Vaccine Efficacy","paramValue":"90.3","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"62.7","estimateComment":"Confidence intervals for the protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990)."}]},{"type":"PRIMARY","title":"% of Participants With Moderate to Severe Diarrhea","description":"Determine whether a single dose of PXVX0200 provides significant greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination. The primary endpoint was the occurrence of moderate or severe (\\>/= 3 liters) of diarrhea.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Ninety days after vaccination","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10\\^8 to 2x10\\^9 CFU in a liquid suspension"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1"},{"groupId":"OG001","value":"59.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The lower, two sided 95% confidence bound on protective efficacy must be \\>/= 30%.","paramType":"Vaccine Efficacy","paramValue":"79.5","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"49.9","estimateComment":"Confidence intervals for the protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990)."}]},{"type":"SECONDARY","title":"Total Weight of Diarrheal Stools Following the 10 Day Cholera Challenge","description":"Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 10 day cholera challenge.","populationDescription":"Intent to Treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"mL","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"309","lowerLimit":"154","upperLimit":"18164"},{"groupId":"OG001","value":"4524","lowerLimit":"140","upperLimit":"24374"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"0.0073","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Total Weight of Diarrheal Stools Following the 90 Day Cholera Challenge","description":"Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 90 day cholera challenge.","populationDescription":"Intent to Treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"mL","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"603","lowerLimit":"22","upperLimit":"9950"},{"groupId":"OG001","value":"4524","lowerLimit":"140","upperLimit":"24374"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"33 participants were challenge 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"% of Participants With Diarrhea of Any Severity Following a 10 Day Cholera Challenge","description":"Incidence of mild or worse (any severity) diarrhea following the 10 day cholera challenge.","populationDescription":"Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"% of participants","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"},{"groupId":"OG001","value":"92.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","paramType":"Vaccine Efficacy","paramValue":"84.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"67.0","ciUpperLimit":"100.0","estimateComment":"Confidence interval for the protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990)."}]},{"type":"SECONDARY","title":"% of Participants With Diarrhea of Any Severity Following a 90 Day Challenge","description":"Incidence of mild or worse (any severity) diarrhea following the 90 day cholera challenge.","populationDescription":"Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"% of participants","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5"},{"groupId":"OG001","value":"92.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","paramType":"Vaccine Efficacy","paramValue":"50.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"33.6","ciUpperLimit":"66.8","estimateComment":"Confidence interval for protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990)."}]},{"type":"SECONDARY","title":"% of Participants With Fever Following the 10 Day Cholera Challenge","description":"Incidence of mild or worse fever following the 10 day cholera challenge.","populationDescription":"Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"% of participants","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"27.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"0.0025","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"% of Participants With Fever Following the 90 Day Cholera Challenge","description":"Incidence of mild or worse fever following the 90 day cholera challenge.","populationDescription":"Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"% of participants","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"27.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"0.0159","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Number of Days With Fecal Shedding Following 10 Day Challenge","description":"Number of days of fecal shedding of wild type V. cholerae following 10 Day Challenge.","populationDescription":"Intent to treat (ITT) population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Days","timeFrame":"Through 10 Days post challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10\\^8 to 2x10\\^9 CFU in a liquid suspension"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG001","value":"3.0","lowerLimit":"3.0","upperLimit":"4.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Number of Days With Fecal Shedding Following 90 Day Challenge","description":"Number of days of fecal shedding of wild type V. cholerae following 90 Day Challenge","populationDescription":"Intent to treat (ITT) population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Days","timeFrame":"Through 10 days following challenge","groups":[{"id":"OG000","title":"PXVX0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10\\^8 to 2x10\\^9 CFU in a liquid suspension"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.0","upperLimit":"3.0"},{"groupId":"OG001","value":"3.0","lowerLimit":"3.0","upperLimit":"4.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"# of Days With Positive Stool Culture Following 10 Day Cholera Challenge","description":"Total number of days with a positive stool culture following the 10 Day Cholera challenge.","populationDescription":"Intent to treat (ITT) comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PVXV0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.20"},{"groupId":"OG001","value":"3.3","spread":"1.01"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"# of Days With Positive Stool Culture Following 90 Day Cholera Challenge","description":"Total number of days with a positive stool culture following 90 Day Cholera Challenge","populationDescription":"Intent to treat (ITT) comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"Through 10 Days following challenge","groups":[{"id":"OG000","title":"PVXV0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.41"},{"groupId":"OG001","value":"3.3","spread":"1.01"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"% of Participants With Reactogenicity, Diarrhea, Fever or Unsolicited Adverse Events Following Vaccination","description":"Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever following vaccination (through Day 8).\n\nIncidence and severity of unsolicited adverse events following vaccination (through Day 29).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"% of participants","timeFrame":"Following vaccination (Days 1 - 8) and to Day 29","groups":[{"id":"OG000","title":"PVXV0200","description":"Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10\\^8 to 2x10\\^9 CFU in a liquid suspension"},{"id":"OG001","title":"Placebo","description":"Biological: Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"% of Subjects with Reactogenicity","categories":[{"measurements":[{"groupId":"OG000","value":"49.5"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"% of Subjects with Diarrhea Symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"3.0"}]}]},{"title":"% of Subjects with Fever Symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"1.0"}]}]},{"title":"% of Subjects with Unsolicited AEs","categories":[{"measurements":[{"groupId":"OG000","value":"17.9"},{"groupId":"OG001","value":"16.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Unsolicited adverse events were recorded for each vaccine or placebo recipient from the day of vaccination through 28 days after vaccination or 28 days after challenge, whichever was later. SAEs and medically attended AEs were recorded through the end of the follow-up period (Day 181).","eventGroups":[{"id":"EG000","title":"PVXV0200","description":"Biological: PXVX0200\n\nSingle dose; liquid suspension after reconstitution with buffer; 5x10\\^8 CFU.","deathsNumAffected":0,"deathsNumAtRisk":95,"seriousNumAffected":0,"seriousNumAtRisk":95,"otherNumAffected":17,"otherNumAtRisk":95},{"id":"EG001","title":"Placebo","description":"Biological: Placebo physiological saline","deathsNumAffected":0,"deathsNumAtRisk":102,"seriousNumAffected":2,"seriousNumAtRisk":102,"otherNumAffected":17,"otherNumAtRisk":102}],"seriousEvents":[{"term":"Hospitalization","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Placebo recipient 01047 was hospitalized for orthopedic surgery considered unrelated to vaccination.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Hyperkalemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Placebo recipient 03019 developed potentially life-threatening hyperkalemia 3 days post-challenge and was considered unrelated to vaccination.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]}],"otherEvents":[{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Gastrointestinal sounds abnormal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":4,"numAtRisk":102}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Feeling Hot","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Chlamydial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Upper Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":95},{"groupId":"EG001","numAffected":2,"numAtRisk":102}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Sports injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":2,"numAtRisk":102}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":3,"numAtRisk":102}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":2,"numAtRisk":102}]},{"term":"Throat irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":0,"numAtRisk":102}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":95},{"groupId":"EG001","numAffected":2,"numAtRisk":102}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":95},{"groupId":"EG001","numAffected":1,"numAtRisk":102}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"David Cassie, Scientist, Clinical Research","organization":"Emergent BioSolutions Canada Inc.","email":"dcassie@ebsi.com","phone":"204-275-4589"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D002771","term":"Cholera"}],"ancestors":[{"id":"D014735","term":"Vibrio Infections"},{"id":"D016905","term":"Gram-Negative Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}